Myleran (Busulfan)

Busulfan exerts its effect by alkylating DNA strands, creating cross‑links that prevent DNA replication and transcription. This disruption leads to cell cycle arrest and apoptosis, especially in rapidly dividing hematopoietic and leukemic cells, thereby reducing disease burden and preparing the marrow for donor cell engraftment.

The specific dose of Myleran is individualized by the treating physician based on the patient’s diagnosis, body surface area, liver function, and intended use (e.g., leukemia treatment versus transplant conditioning). Only a qualified healthcare professional should determine the appropriate dosing schedule.

The safety of busulfan in pregnancy and lactation has not been established. It is classified as contraindicated for use in pregnant or nursing women because of potential teratogenic and toxic effects on the fetus or infant. Women of child‑bearing potential should use effective contraception during treatment.

To request Myleran, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Busulfan is often compared with total body irradiation (TBI) or other alkylators such as cyclophosphamide. Compared with TBI, busulfan offers a purely pharmacologic approach without radiation exposure, but it requires careful therapeutic drug monitoring to avoid toxicity. Unlike cyclophosphamide, busulfan has a different metabolic pathway and distinct side‑effect profile, including a higher risk of hepatic veno‑occlusive disease.

Myleran tablets should be stored at temperatures below 25 °C, in their original blister pack, protected from moisture and direct sunlight. Do not refrigerate or freeze the product. Keep out of reach of children and store in a secure, dry location.

Myleran is supplied as oral tablets that are taken by mouth with water, usually on an empty stomach to improve absorption. The exact schedule (single dose, divided doses, or multiple days) is determined by the prescribing clinician based on the therapeutic intent and patient factors.

The most serious adverse events include pulmonary fibrosis, hepatic veno‑occlusive disease, severe bone‑marrow suppression leading to infections or bleeding, and seizures, particularly at high plasma concentrations. Patients should be monitored closely for respiratory symptoms, liver dysfunction, and neurologic changes throughout therapy.

Myleran is contraindicated in patients with known hypersensitivity to busulfan or any tablet excipients, those with pre‑existing severe pulmonary disease, uncontrolled hepatic impairment, or active uncontrolled infections. It should also be avoided in pregnant or nursing women and in individuals for whom alternative, less toxic conditioning regimens are available.